SecBot SecBot

ACXP

Acurx Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001736243 Biotech & Drug Discovery
$1.13 −0.00 (−0.44%)
Oct 23 4:00 PM ET · prev $1.14
Market cap
$6.3M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
🔒 Subscribers only
1 year
−82.6%
from $6.51 · Oct 24
30 days
−16.5%
from $1.36
52-week range
$1.10–6.63
−83% from high · low Oct 16
Avg volume 20D
77.1K
shares / day
Short interest
111.7K
≈2.0% of shares · −10.0%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH The SEC declared effective Acurx Pharmaceuticals' S-1 registration statement (File No. 333-298801) on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −10.0% to 111.7K shares. 1.0 days to cover, ≈2.0% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM15,727$24.4K
BARCLAYS PLCTRIM281$436.00
GROUP ONE TRADING LLCTRIM95$147.00
UBS Group AGNEAR_EXIT3$5.00
JANE STREET GROUP, LLCDOUBLED54,642$202.7K
GEODE CAPITAL MANAGEMENT, LLCADD24,819$92.1K
UBS Group AGDOUBLED6,312$23.4K
OSAIC HOLDINGS, INC.TRIM100$249.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 29, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Apr 20, 2026
Shawah Robert G.
Chief Financial Officer
AWARD25,900 sh
Apr 20, 2026
LUCI DAVID P
President and CEO
AWARD37,100 sh
Apr 20, 2026
DELUCCIA ROBERT J
Director
AWARD37,100 sh
Apr 20, 2026
Scodari Joseph C
Director
AWARD2,150 sh
Apr 20, 2026
HARRISON THOMAS L
Director
AWARD2,150 sh
Apr 20, 2026
Donohue James J.
Director
AWARD2,150 sh
Apr 20, 2026
DEAN JACK H
Director
AWARD2,150 sh
Apr 20, 2026
Sailer Carl
Director
AWARD2,150 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
111,697
shares short
-10.0%
vs prior settlement
1.0
days to cover
≈2.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 SEC
The SEC declared effective Acurx Pharmaceuticals' S-1 registration statement (File No. 333-298801) on September 17…
EFFECT — Impact 5/10
Aug 14, 2026 SEC
Acurx Pharmaceuticals reported Q2 2026 EPS of -$0.53, a 26% miss versus the $0.42 consensus, reflecting higher R&D…
PRESS-RELEASE — Impact 5/10
Aug 14, 2026 Earnings
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — TRIM
15,727 shares ($24.4K)
Jun 30, 2026 Inst.
BARCLAYS PLC — TRIM
281 shares ($436.00)
May 4, 2026 SEC
Acurx Pharmaceuticals filed an S-1 to register 1,300,000 shares for resale by Lincoln Park Capital Fund, LLC under an…
S-1 — Impact 5/10
Apr 20, 2026 Insider
Shawah Robert G. was granted 25,900 shares
Chief Financial Officer
Apr 20, 2026 Insider
LUCI DAVID P was granted 37,100 shares
President and CEO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 14, 2026
Earnings
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage…
Aug 14, 2026
Earnings date
ACXP Q2 2026 Earnings Scheduled — 2026-08-14
Aug 12, 2026
Press release
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage…
Jul 8, 2026
Earnings
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage…
May 12, 2026
Earnings date
ACXP Q1 2026 Earnings Scheduled — 2026-05-12

SecBot reports

6 filings · 0 bullish · 4 bearish · 1 mixed · 1 neutral
All ACXP filing & press-release reports (6)